Anti-eAg Antibody from X63 Fused CD19 B Cell Hybridoma (D4)
Invented by Anders Elm Pedersen , Mogens H Claesson
Invented at University of Copenhagen
- Datasheet
- References (1)
- Inventor Info
Info
Catalogue Number | 153818 |
Applications | N/A |
Antigen/Gene or Protein Targets | Enteroantigen |
Reactivity | N/A |
Relevance |
Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAg’s in experimental colitis, and potentially, in human IBD. |
Notes | Hybridoma cell lines profit from the addition of 10 ng/ml of human IL-6 in the growth media. |
Research Area | Other |
References: 1 entry
In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody.
Add a reference
References: 1 entry
In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody.
Add a reference
Inventor Information
Inventors
|
Anders Elm Pedersen |
|
Mogens H Claesson |